Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nursing Shortage Eases With Recession's Help
"The nation"s deep recession is helping to alleviate the decade-long nursing shortage, as workers who had left the field in better times are returning in droves," the Wall Street Journal reports. The paper quotes a study, one of six papers on the nursing workforce published today in the journal Health Affairs, that found "nearly a quarter-million nurses entered the work force in 2007-08, an 18% surge that was the largest two-year increase in at least three decades." Many of them had left nursing, but "re-entered the work force to compensate for a spouse"s lost income or health benefits, the study said." The increase is "particularly remarkable at a time when the U.S. economy has shed more than six million jobs, helping to solidify the profession"s "recession-proof" image." The study found that the surge in new nurses is due to "efforts to expand nursing schools, attract more young people into the field and improve working conditions," along with an increase in the number of foreign-born nurses.

BSD Receives FDA Humanitarian Use Designation For The BSD-2000 Hyperthermia System
BSD Medical Corporation (NASDAQ:BSDM) announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Use Device (HUD) designation for the company"s BSD-2000 Hyperthermia System for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy. This is the first of the two steps required to obtain Humanitarian Device Exemption (HDE) marketing approval, which requires BSD Medical to demonstrate the device"s safety and probable benefit in treating a disease or condition that affects fewer than 4,000 individuals in the United States per year. Now that FDA has granted the Humanitarian Use Designation for the BSD-2000, which confirms that the intended use population is fewer than 4,000 patients per year, BSD can file an HDE submission with the FDA. FDA has 75 days from the date of receipt of the HDE submission to grant or deny an HDE application. This period includes a 30-day filing period during which FDA determines whether the HDE application is sufficiently complete to permit substantive review. During this review, FDA may refine the indications for use which received HUD designation to finalize the indications for use for which HDE approval will be granted. This decision will be based on the data that are available to support the device"s HDE application. The company believes that the data previously submitted to FDA and reviewed by the agency in the company"s pending PMA application can be used to support the HDE approval, and that this previous review may expedite marketing approval for the BSD-2000.
News of the day
Health Care Providers Need Res And Support To Help Female Victims Of Abuse, According To Pitt Study
Health professionals are required to provide help for victims of intimate partner violence (IPV), yet many do not even discuss the issue with their patients, according to a University of Pittsburgh study in the current issue of Violence and Victims.
Health Insurance

Diabetic Retinopathy Stopped By Natural Compound

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a natural compound to stop one of the leading causes of blindness in the United States. The research appears online this month in the journal Diabetes, a publication of the American Diabetes Association. The discovery of the compound"s function in inflammation and blood vessel formation related to eye disease means scientists can now develop new therapies - including eye drops - to stop diabetic retinopathy, a disease which affects as many as five million Americans with Type 1 and Type 2 diabetes. "There is no good treatment for retinopathy, which is why we are so excited about this work. This opens an entirely new area for pharmaceutical companies to target," said Jay Ma, the principal investigator on the project and a research partner at the OU Health Sciences Center, Dean A. McGee Eye Institute and the Harold Hamm Oklahoma Diabetes Center. Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. It is caused by changes in blood vessels of the retina, the light-sensitive tissue at the back of the eye. In some people with diabetic retinopathy, blood vessels may swell and leak fluid. In other people, abnormal new blood vessels grow on the surface of the retina. Over time, diabetic retinopathy can get worse and cause some vision loss or blindness. Oklahoma researchers found that this inflammation and leakage is caused by an imbalance of two systems in the eye. To restore balance, they delivered the new compound to cells using nanoparticle technology. The treatment in research models stopped the leakage, blocked inflammation and kept unwanted blood vessels from growing. Researchers are now testing the compound"s uses for cancer and age-related macular degeneration. Dr. Ma"s research is funded by the American Diabetes Association and the National Institutes of Health. Diane Clay University of Oklahoma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009